Sanofi (SNY)
(Delayed Data from NSDQ)
$51.26 USD
-1.59 (-3.01%)
Updated Nov 6, 2024 03:59 PM ET
Pre-Market: $51.43 +0.17 (0.33%) 9:16 AM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$51.26 USD
-1.59 (-3.01%)
Updated Nov 6, 2024 03:59 PM ET
Pre-Market: $51.43 +0.17 (0.33%) 9:16 AM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
Zacks News
Sanofi's (SNY) Q2 Earnings Surpass Estimates, Sales Miss
by Zacks Equity Research
Sanofi (SNY) beats earnings but misses on sales in the second quarter of 2018 owing to currency headwinds and struggling diabetes and cardiovascular unit.
Regeneron (REGN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors' focus will be on the company's performance, particularly on Eylea and Dupixient's uptake during Regeneron's (REGN) second-quarter earnings call.
ImmunoGen (IMGN) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
ImmunoGen (IMGN) reports wider-than-expected loss in Q2. Lower license and milestone fees result in substantial decrease in year-over-year revenues.
6 European Stocks to Shun on Tapered IMF Outlook
by Sanghamitra Saha
IMF lowered its growth projection for in Germany, France and Italy. Time to avoid these sell-ranked stocks?
Regulus Stock Plunges on Cash Concerns Despite Restructuring
by Zacks Equity Research
Regulus Therapeutics (RGLS) announces strategic and restructuring plans to extend cash runway. However, investors remain skeptical.
Sanofi's Blood Clotting Drug Gets Positive CHMP Opinion
by Zacks Equity Research
Sanofi's (SNY) Cablivi for treating acquired thrombotic thrombocytopenic purpura nears approval with CHMP recommendation.
Sanofi (SNY) Finalizes Deal for European Generic Unit Sale
by Zacks Equity Research
Sanofi (SNY) finalizes sale of its European generic unit, Zentiva, for $2.2 billion.
Amgen's Repatha Reduces Bad Cholestrol in Type II Diabetes
by Zacks Equity Research
Amgen's (AMGN) Repatha significantly reduces LDL-C and non-HDL-C in patients with type II diabetes and hypercholesterolemia or mixed dyslipidemia.
Will Roche's (RHHBY) Acquisition Spree Revive the Top Line?
by Zacks Equity Research
Roche (RHHBY) is looking to boost its portfolio with some strategic acquisitions and we expect further activities on this front.
5 Biotech Stocks Under $10 Worthy of Investors' Attention
by Indrajit Bandyopadhyay
Small biotech stocks are good bets with lower market cap as well as share price.
Alexion-Complement Pharma Tie Up to Treat Neuro Disorders
by Zacks Equity Research
Alexion (ALXN) teams up with Complement Pharma to co-develop its C6 inhibitor, CP010, for neurodegenerative disorders.
Alnylam Reports Positive Data on Lumasiran in Renal Disease
by Zacks Equity Research
Alnylam (ALNY) announces positive results from the ongoing study on lumasiran in Primary Hyperoxaluria Type 1 (PH1) patients.
The Zacks Analyst Blog Highlights: Mastercard, VMware, Sanofi, Twitter and State Street
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Mastercard, VMware, Sanofi, Twitter and State Street
3 Stocks Raising Hopes in Troubled Large-Cap Pharma Industry
by Indrajit Bandyopadhyay
Though the large-cap pharma industry is struggling currently, there are a few stocks that are performing well.
5 Biotech Stocks to Boost Your Portfolio's Health This Year
by Kinjel Shah
Though the biotech industry is down this year, there are still a few stocks which can strengthen your portfolio.
The Zacks Analyst Blog Highlights: UnitedHealth, United Technologies, Eni, Sanofi and Discovery
by Zacks Equity Research
The Zacks Analyst Blog Highlights: UnitedHealth, United Technologies, Eni, Sanofi and Discovery
Biotech Stock Roundup: FDA Gives Nod to Amgen's Drugs, EU Approves Exelixis' Cabometyx
by Zacks Equity Research
Label expansion of a few prominent drugs along with pipeline updates were the key areas of focus for investors in the biotech space.
Top Research Reports for UnitedHealth, United Technologies & Eni
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth (UNH), United Technologies (UTX) and Eni (E).
Amgen's (AMGN) Repatha Gains EU Nod to Include Outcomes Data
by Zacks Equity Research
Amgen (AMGN) gets European Commission's approval to incorporate a new indication into the European label of its PCSK9 inhibitor, Repatha.
Sanofi Eczema Drug Dupixent Succeeds in Adolescents Study
by Zacks Equity Research
Sanofi (SNY) announces positive results from a phase III study evaluating Dupixent for the treatment of moderate-to-severe atopic dermatitis in adolescents.
BioMarin Begins Mid Stage Study on Gene Therapy Candidate
by Zacks Equity Research
BioMarin (BMRN) initiates a mid-stage study to evaluate its gene therapy candidate, valoctocogene roxaparvovec for treating in AAV5+ severe hemophilia A.
Alnylam's (ALNY) Q1 Loss Wider than Expected, Sales Miss
by Zacks Equity Research
Alnylam (ALNY) incurs narrower-than-expected loss and missed revenue estimates in Q1. With several pipeline related events lined up and potential approval for patisiran, we expect investor focus to remain on the related updates.
Emergent (EBS) Misses on Q1 Earnings, Retains 2018 View
by Zacks Equity Research
Emergent's (EBS) earnings and revenues lag estimates in Q1. However, the top line improves marginally year over year, driven by higher contract manufacturing revenues.
Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q1
by Zacks Equity Research
Immune Design (IMDZ) posts narrower-than-expected loss and misses revenue estimates in Q1. The company remains on track to start a pivotal phase III study for CMB305 on patients with synovial sarcoma.
Regeneron (REGN) Q1 Earnings Top, Sales Lag, Updates View
by Zacks Equity Research
Regeneron's (REGN) first-quarter results were mixed as earnings beat expectations while sales missed the same. Nevertheless, Eylea sales were impressive.